Advanced glycation end products and the kidney

被引:301
|
作者
Bohlender, JM [1 ]
Franke, S [1 ]
Stein, G [1 ]
Wolf, G [1 ]
机构
[1] Univ Klin Jena, Innere Med Klin 3, Dept Internal Med 3, Jena, Germany
关键词
RAGE; diabetic nephropathy; progression of renal disease; inflammation; glycoxidation;
D O I
10.1152/ajprenal.00398.2004
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Advanced glycation end products (AGEs) are a heterogeneous group of protein and lipids to which sugar residues are covalently bound. AGE formation is increased in situations with hyperglycemia ( e. g., diabetes mellitus) and is also stimulated by oxidative stress, for example in uremia. It appears that activation of the renin-angiotensin system may contribute to AGE formation through various mechanisms. Although AGEs could nonspecifically bind to basement membranes and modify their properties, they also induce specific cellular responses including the release of profibrogenic and proinflammatory cytokines by interacting with the receptor for AGE ( RAGE). However, additional receptors could bind AGEs, adding to the complexity of this system. The kidney is both: culprit and target of AGEs. A decrease in renal function increases circulating AGE concentrations by reduced clearance as well as increased formation. On the other hand, AGEs are involved in the structural changes of progressive nephropathies such as glomerulosclerosis, interstitial fibrosis, and tubular atrophy. These effects are most prominent in diabetic nephropathy, but they also contribute to renal pathophysiology in other nondiabetic renal diseases. Interference with AGE formation has therapeutic potential for preventing the progression of chronic renal diseases, as shown from data of animal experiments and, more recently, the first clinical trials.
引用
收藏
页码:F645 / F659
页数:15
相关论文
共 50 条
  • [31] Advanced glycation end products and diabetic retinopathy
    Ross Milne
    Seymour Brownstein
    Amino Acids, 2013, 44 : 1397 - 1407
  • [32] Advanced glycation end products, diabetes and ageing
    Nass, N.
    Bartling, B.
    Santos, A. Navarrete
    Scheubel, R. J.
    Boergermann, J.
    Silber, R. E.
    Simm, A.
    ZEITSCHRIFT FUR GERONTOLOGIE UND GERIATRIE, 2007, 40 (05): : 349 - 356
  • [33] Advanced Glycation End Products and Diabetic Retinopathy
    Chen, M.
    Curtis, T. M.
    Stitt, A. W.
    CURRENT MEDICINAL CHEMISTRY, 2013, 20 (26) : 3234 - 3240
  • [34] Advanced glycation end products, diabetes, and the brain
    Coker, Laura H.
    Wagenknecht, Lynne E.
    NEUROLOGY, 2011, 77 (14) : 1326 - 1327
  • [35] ADVANCED GLYCATION END PRODUCTS IN SYSTEMIC SCLEROSIS
    Triginer, L.
    Tio, L.
    Carrion, I.
    Guillen-Del-Castillo, A.
    Ribes, A.
    Valencia Muntala, L.
    Monfort, J.
    Salman, T. C.
    Pros, A.
    Narvaez, J.
    Simeon Aznar, C. P.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1655 - 1656
  • [36] Advanced glycation end products, dementia, and diabetes
    Lovestone, Simon
    Smith, Ulf
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2014, 111 (13) : 4743 - 4744
  • [37] Role of dietary advanced glycation end products
    Clifton, Peter
    Keogh, Jennifer
    CURRENT OPINION IN LIPIDOLOGY, 2017, 28 (06) : 514 - 515
  • [38] Zinc against advanced glycation end products
    Kheirouri, Sorayya
    Alizadeh, Mohammad
    Maleki, Vahid
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2018, 45 (06) : 491 - 498
  • [39] Advanced glycation end products and diabetic complications
    Stitt, AW
    Jenkins, AJ
    Cooper, ME
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2002, 11 (09) : 1205 - 1223
  • [40] The Role of Advanced Glycation End Products on Dyslipidemia
    Vekic, Jelena
    Vujcic, Sanja
    Bufan, Biljana
    Bojanin, Dragana
    Al-Hashmi, Khamis
    Al-Rasadi, Khaild
    Stoian, Anca Pantea
    Zeljkovic, Aleksandra
    Rizzo, Manfredi
    METABOLITES, 2023, 13 (01)